We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+11.22%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$10.3B
AUM Growth
+$1.27B
Cap. Flow
+$755M
Cap. Flow %
7.32%
Top 10 Hldgs %
81.62%
Holding
100
New
12
Increased
23
Reduced
8
Closed
11

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$212M
2
INSM icon
Insmed
INSM
+$178M
3
ALKS icon
Alkermes
ALKS
+$57.4M
4
RVMD icon
Revolution Medicines
RVMD
+$54.9M
5
GPCR icon
Structure Therapeutics
GPCR
+$47.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$23.2M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$22.3M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$17.6M
4
TSVT
2seventy bio
TSVT
+$12.3M
5
BCAX
Bicara Therapeutics
BCAX
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TECX
76
Tectonic Therapeutic
TECX
$555M
$1.99M 0.02%
100,000
– –
CADL icon
77
Candel Therapeutics
CADL
$708M
$1.8M 0.02%
355,112
-2,082,077
-85% -$10.7M
TARA icon
78
Protara Therapeutics
TARA
$218M
$1.63M 0.02%
536,832
– –
VTVT icon
79
vTv Therapeutics
VTVT
$125M
$1.46M 0.01%
97,314
– –
RCKT icon
80
Rocket Pharmaceuticals
RCKT
$344M
$1.35M 0.01%
552,079
-545,000
-50% -$2.76M
CTNM
81
Contineum Therapeutics
CTNM
$551M
$1.24M 0.01%
312,500
– –
HOOK
82
DELISTED
HOOKIPA Pharma
HOOK
$1.02M 0.01%
812,814
– –
NMRA icon
83
Neumora Therapeutics
NMRA
$309M
$759K 0.01%
1,034,600
– –
GBIO
84
DELISTED
Generation Bio
GBIO
$623K 0.01%
194,495
– –
ALGS icon
85
Aligos Therapeutics
ALGS
$26.9M
$599K 0.01%
83,055
– –
TYRA icon
86
Tyra Biosciences
TYRA
$1.89B
$102K ﹤0.01%
10,607
– –
ACRV icon
87
Acrivon Therapeutics
ACRV
$62.9M
$27.1K ﹤0.01%
22,809
– –
SRZNW icon
88
Surrozen Inc Warrant
SRZNW
$36.6K
$15.1K ﹤0.01%
833,333
– –
CMPX icon
89
Compass Therapeutics
CMPX
$364M
– –
-547,498
Closed -$1.04M
CNTA
90
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-1,227,178
Closed -$17.6M
CRSP icon
91
CRISPR Therapeutics
CRSP
$4.72B
– –
-654,099
Closed -$22.3M
DYN icon
92
Dyne Therapeutics
DYN
$4.24B
– –
-672,096
Closed -$7.03M
IONS icon
93
Ionis Pharmaceuticals
IONS
$9.07B
– –
-357,915
Closed -$10.8M
IPSC icon
94
Century Therapeutics
IPSC
$373M
– –
-241,684
Closed -$115K
CYPH
95
Cypherpunk Technologies Inc
CYPH
$65.4M
– –
-404,744
Closed -$123K
PRME icon
96
Prime Medicine
PRME
$556M
– –
-1,028,466
Closed -$2.05M
RGLS
97
DELISTED
Regulus Therapeutics
RGLS
– –
-2,694,044
Closed -$4.71M
TSVT
98
DELISTED
2seventy bio
TSVT
– –
-2,497,526
Closed -$12.3M
BCAX
99
Bicara Therapeutics
BCAX
$1.75B
– –
-833,333
Closed -$10.9M
OPT
100
DELISTED
Opthea Limited American Depositary Shares
OPT
$0 ﹤0.01%
2,087,320
– –
1 2 3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Baker Bros. Advisors held 100 positions worth $10.3B, up 14% from $9.04B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors deployed $755M of net new capital in Q2 2025, opening 12 new positions and adding to 23 existing holdings. Its largest new stake was Viridian Therapeutics: 1,744,406 shares worth $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was argenx, an estimated $23.2M trimmed.

  • Baker Bros. Advisors's largest Q2 2025 buy was Viridian Therapeutics: 1,744,406 shares worth $24.4M.
  • Baker Bros. Advisors added most to Summit Therapeutics in Q2 2025, an estimated $212M increase.
  • Baker Bros. Advisors's biggest Q2 2025 reduction was argenx, cutting an estimated $23.2M.
  • Baker Bros. Advisors fully exited CRISPR Therapeutics in Q2 2025, selling an estimated $22.3M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $10.3B portfolio in Q2 2025.
  • Baker Bros. Advisors opened 12 new positions and closed 11 in Q2 2025.
  • Baker Bros. Advisors's portfolio value rose 14% quarter-over-quarter to $10.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.